论文信息 - The commercial genetic testing landscape for Parkinson's disease. - 字舞流文

The commercial genetic testing landscape for Parkinson's disease.

I. König | C. Blauwendraat | M. Farrer | M. Cookson | K. Marder | J. Shulman | S. Schneider | T. Foroud | K. Lohmann | T. Simuni | N. Hattori | A. Brice | S. Lesage | M. Merello | J. Corvol | K. Nudelman | E. Valente | O. Suchowersky | S. Bardien | I. Mata | M. Nance | R. Saunders-Pullman | C. Sue | S. Farhan | D. Mascalzoni | S. Sardi | A. Shalash | T. Lynch | Z. Gan-Or | C. Klein | A. West | B. Fiske | P. Mistry | M. Schwarzschild | S. Chung | C. Thaxton | T. Bardakjian | N. Mencacci | D. Craig | G. Riboldi | D. Raymond | A. Thaler | C. Marras | O. Ross | E. Gatto | V. Bonifati | J. Beck | J. Fong | E. Fon | T. Tropea | Samuel P. Strom | A. Singleton | Yunlong Liu | B. Schüle | Gian Pal | M. Salari | R. Alcalay | S. Longerich | H. Elloumi | S. Mohan | I. Novaković | J. Schulze | S. Padmanabhan | T. Courtin | R. Blake | Priscila D Hodges | E. Sammler | Anne Hall | L. Cook | C. Gabbert | J. Verbrugge | A. Naito | Amasi Kumeh | D. Alessi | Emily Forbes | Gill Chao | J. Peterschmitt | Lara M. Lange | M. Grigorian | L. Lange | Gian D Pal

[1] I. König,et al. Genotype–Phenotype Relations for the Atypical Parkinsonism Genes:MDSGene Systematic Review , 2021, Movement disorders : official journal of the Movement Disorder Society.

[2] GP2: The Global Parkinson's Genetics Program , 2021, Movement disorders : official journal of the Movement Disorder Society.

[3] T. Foroud,et al. Genetic Testing for Parkinson Disease: Are We Ready? , 2020, Neurology. Clinical practice.

[4] P. Bauer,et al. The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings , 2020, Movement disorders : official journal of the Movement Disorder Society.

[5] S. Schneider,et al. Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism , 2020, Neurotherapeutics.

[6] Sonja W. Scholz,et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[7] Birgit Funke,et al. Diagnostic gene sequencing panels: from design to report—a technical standard of the American College of Medical Genetics and Genomics (ACMG) , 2019, Genetics in Medicine.

[8] K. Marder,et al. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists , 2019, Genetics in Medicine.

[9] C. Blauwendraat,et al. The role of monogenic genes in idiopathic Parkinson’s disease , 2019, Neurobiology of Disease.

[10] C. Klein,et al. 'Atypical' Parkinson's disease - genetic. , 2019, International review of neurobiology.

[11] A. Brice,et al. The genetic landscape of Parkinson's disease. , 2018, Revue neurologique.

[12] Kathryn A Phillips,et al. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? , 2018, Health affairs.

[13] R. Alcalay,et al. Genetic Forms of Parkinson's Disease , 2017, Seminars in Neurology.

[14] O. Tysnes,et al. Epidemiology of Parkinson’s disease , 2017, Journal of Neural Transmission.

[15] S. Kolb,et al. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians , 2016, Genetics in Medicine.

[16] L. Shulman,et al. Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. , 2016, Current opinion in neurology.

[17] Nora Husain,et al. The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency , 2012, Nucleic Acids Res..

[18] K. Marder,et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations , 2009, Neurology.

[19] J. Burgunder,et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias , 2009, European journal of neurology.